Cite
HARVARD Citation
Terui, Y. et al. (2021). A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma. Cancer science. 112 (7), pp. 2845-2854. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Terui, Y. et al. (2021). A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma. Cancer science. 112 (7), pp. 2845-2854. [Online].